Basic Information
| LncRNA/CircRNA Name | LeXis |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot etc. |
| Sample | OS tissues, cell lines (Nhost, KHOS, 143b, LM7, U2OS, and MG-63) |
| Expression Pattern | up-regulated |
| Function Description | LeXis expression was upregulated in OS tissues. Increased LeXis expression was significantly correlated with high tumor stage, large tumor size, and poor prognosis. LeXis increased CTNNB1 expression by functioning as a ceRNA of CTNNB1 against miR-199a.Moreover, LeXis increased CTNNB1 expression by functioning as a ceRNA of CTNNB1 against miR-199a. The 5-year survival rate of patients with OS having distant metastases is approximately 30% . |
| Pubmed ID | 28744406 |
| Year | 2017 |
| Title | Long noncoding RNA LeXis promotes osteosarcoma growth through upregulation of CTNNB1 expression. |
External Links
| Links for LeXis | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |